Taysha Gene Therapies, Inc. (TSHA) AI Stock Analysis
TSHA AI stock analysis summary
AI ResearchTaysha Gene Therapies, Inc. (TSHA) is a clinical-stage biotechnology company developing adeno-associated virus-based gene therapies for central nervous system disorders. The company generated $5.5M in trailing twelve-month revenue while recording an operating margin of -2792.3% and a net income of -$109.0M in FY2025. With $455.4M in cash and short-term investments as of June 30, 2026, TSHA maintains balance sheet liquidity to support ongoing operations.
- Market cap
- $1.18B
- Revenue (TTM)
- $5.5M
- P/E
- —
- 1Y return
- -28.7% S&P 500 16.8%
- Avg. target
- $13.00 259.1% vs last close
Bull case
- TSHA generated 171.3% year-over-year quarterly revenue growth in the period ended June 30, 2026.
- The balance sheet provides liquidity with $455.4M in cash and short-term investments and net cash of $399.9M as of June 30, 2026.
- Analysts maintain 10 Strong Buy ratings and a mean price target of $13.00, which is 259.1% above the last close.
Bear case
- The company continues to produce significant losses, with FY2025 net income of -$109.0M and free cash flow of -$93.8M.
- TSHA stock fell 79.8% over the past 5 years, significantly underperforming the S&P 500 return of 83.0%.
- Valuation multiples remain elevated, with a price-to-sales ratio of 215.0x compared to the US-listed Healthcare median of 4.1x.
What Taysha Gene Therapies does
Taysha Gene Therapies, Inc. is a pioneering gene therapy company dedicated to advancing adeno-associated virus-based treatments for monogenic diseases of the central nervous system. Its development pipeline includes TSHA-120 for giant axonal neuropathy, TSHA-102 for Rett syndrome, TSHA-121 and TSHA-118 for CLN1 disease, TSHA-105 for SLC13A5 Deficiency, and TSHA-101 for GM2 gangliosidosis. Founded in 2019 and headquartered in Dallas, Texas, the company maintains a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize treatments for rare genetic disorders.
Growth and profitability
Annual revenue rose from $2.5M in FY2022 to $15.5M in FY2023, fell 46.1% to $8.3M in FY2024, and grew 17.3% to $9.8M in FY2025, resulting in a 3-year revenue CAGR of 57.5%. Gross margin improved from 0.6% in FY2022 to 100.0% in FY2023, FY2024, and FY2025. Operating margin remained deeply negative at -1130.6% in FY2025 alongside R&D expenses of $86.4M. Net income was -$109.0M in FY2025, compared to -$166.0M in FY2022. For the latest quarter ended June 30, 2026, quarterly revenue growth was 171.3% year-over-year, while trailing twelve-month revenue reached $5.5M.
Balance sheet and cash flow
As of June 30, 2026, TSHA held $455.4M in cash and short-term investments alongside total debt of $55.6M, resulting in net cash of $399.9M. Shareholders' equity stood at $387.3M, and total assets were $470.4M. The company reported a current ratio of 17.76 and a debt-to-equity ratio of 0.14. In FY2025, operating cash flow was -$93.1M, free cash flow was -$93.8M, and capital expenditures totaled $738,000. Over 5 years, the company's share count increased 868.4%.
Valuation and performance
With a market cap of $1.18B and an enterprise value of $1.20B, TSHA trades at a price-to-sales multiple of 215.0x and an EV to revenue multiple of 219.0x, compared to the median of its US-listed Healthcare peers of 4.1x. Its price-to-book ratio is 4.1x. Over the past 1 year, the stock fell 28.7%, trailing the S&P 500 return of 16.8%. Over a 5-year period, TSHA shares declined 79.8% while the S&P 500 gained 83.0%.
What analysts expect
Analyst coverage consists of 10 Strong Buy and 3 Buy ratings, with 0 Hold, 0 Sell, and 0 Strong Sell ratings. The mean price target is $13.00, representing a 259.1% premium over the October 16, 2026 closing price of $3.62. For the current fiscal year ending December 31, 2026, analysts estimate revenue of $1.8M and an EPS of -$0.47. TSHA beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 3, 2026.
Key risks and what to watch
- Short interest represents 17.2% of the float as of October 16, 2026.
- Share count increased 868.4% over 5 years, highlighting potential ongoing shareholder dilution.
- Trailing twelve-month operating margin stands at -2792.3% on $5.5M in revenue, indicating substantial operating losses.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this TSHA AI stock analysis
This page is an AI-written research summary of Taysha Gene Therapies, Inc. (TSHA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: TSHA income statement, TSHA balance sheet, TSHA key metrics, TSHA analyst forecast, TSHA chart. See the TSHA stock overview for the latest quote and news.
TSHA AI stock analysis FAQ
Does TSHA pay a dividend?
No, Taysha Gene Therapies does not pay a dividend. Capital is deployed toward research and clinical development, including $86.4M spent on R&D in FY2025.
What is the consensus analyst price target for TSHA?
The mean analyst price target is $13.00, which represents a 259.1% increase from the closing price of $3.62 on October 16, 2026.
How much cash does Taysha Gene Therapies have?
As of June 30, 2026, the company held $455.4M in cash and short-term investments and $55.6M in total debt, leaving net cash of $399.9M.
When does TSHA report its next earnings?
TSHA is scheduled to report its next earnings on November 3, 2026.